Pancreatic Cancer Research

ResearcherNational and Kapodistrian University of AthensNo recent work listed

Stamatios E Theocharis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0930-1657; OpenAlex author ID A5006412575, A5113616781. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
14
Papers, trials and grants by year

2015: 3 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper

Papers 8

  1. The EPH/Ephrin System in Pancreatic Ductal Adenocarcinoma (PDAC): From Pathogenesis to Treatment. Last author DOI 10.3390/ijms24033015↗
  2. Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment? Last author DOI 10.3390/ijms23073620↗
  3. Combinatorial Treatment of Tinzaparin and Chemotherapy can Induce a Significant Antitumor Effectin Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-551892/v1↗
  4. Divulging the Critical Role of HuR in Pancreatic Cancer as a Therapeutic Target and a Means to Overcome Chemoresistance. Last author DOI 10.3390/cancers13184634↗
  5. Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer. Co-author DOI 10.3390/ijms22137053↗
  6. Pregnane X Receptor Expression in Human Pancreatic Adenocarcinoma: Associations With Clinicopathologic Parameters, Tumor Proliferative Capacity, Patients' Surv… Last author DOI 10.1097/mpa.0000000000000405↗
  7. Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferativ… Last author DOI 10.1186/s12876-015-0379-y↗
  8. Elevated Farnesoid X Receptor (FXR) and Retinoid X Receptors (RXRs) expression is associated with less tumor aggressiveness and favourable prognosis in patient… Last author DOI 10.4149/neo_2015_040↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stavros P. Papadakos · 2 shared papers, 2022–2023 · strength 0.44
  2. Pavlos Papakotoulas · 2 shared papers, 2021 · strength 0.25
  3. Panagiotis Sarantis · 2 shared papers, 2021 · strength 0.25
  4. Evangelos S. Felekouras · 2 shared papers, 2021 · strength 0.25
  5. Alexandros Papalampros · 2 shared papers, 2021 · strength 0.25
  6. Evangelos Koustas · 2 shared papers, 2021 · strength 0.25
  7. Michalis V. Karamouzis · 2 shared papers, 2021 · strength 0.25
  8. Athanasios G. Papavassiliou · 2 shared papers, 2021 · strength 0.25
  9. Dimitriοs Schizas · 2 shared papers, 2021 · strength 0.25
  10. Dimitrios Goutas · 1 shared paper, 2021 · strength 0.22
  11. Maria Gazouli · 1 shared paper, 2022 · strength 0.20
  12. Ioannis S. Koutsounas · 3 shared papers, 2015 · strength 0.16
  13. Constantinos Giaginis · 3 shared papers, 2015 · strength 0.16
  14. Christos Damaskos · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.